Skip to main content
. 2020 Aug 14;11:1858. doi: 10.3389/fimmu.2020.01858

Figure 1.

Figure 1

GPR15 counteracts BP-like EBA. The course of skin inflammation in the BP-like EBA mouse model was contrasted in wild-type and Gpr15−/− mice. (A) Progression of disease severity benchmarked as percentage of the total body surface affected by skin lesions (ABSA) over the course of 14 days. (B) Representative pictures of the clinical presentation of wild-type and Gpr15−/− mice on days 4 and 9 of the experiment. (C) Direct immunofluorescence microscopy of perilesional skin for IgG (upper panel) and C3 (lower panel) with white arrows indicating linear depositions of IgG and C3, respectively. Results are presented as mean ± SEM of the ABSA (n = 10 mice/group; pooled from three independent experiments). Results were analyzed by two-way ANOVA and Holm-Sidak's multiple comparison test. *p < 0.05 and ***p < 0.001 for the comparison between wild-type vs. Gpr15−/− mice on the day indicated.